Impact of Archived Minority Populations With M184V/I on DTG/3TC for Maintenance of Viral Suppression
Background: There is limited evidence on the utility of proviral DNA sequencing to guide treatment changes in virologically suppressed persons with HIV (PWH) and prior virologic failures. VOLVER clinical trial aimed to evaluate if proviral DNA could assist in switching to dolutegravir/lamivudine (DTG/3TC) in PWH with history of 3TC resistance. Methods: Open-label single-arm multicentric clinical…